The Cleveland company announced on Wednesday, Dec. 26, that Brad Wertz, a founding investor and chairman of the board since GenomOncology’s inception, will become chairman and CEO as of Jan. 1. Current CEO Manuel Glynias, the founder of GenomOncology, “will remain president and will focus on advancing the technology and product offerings to further accelerate the growth of the company,” the company said in a news release.